ETCAMAH® (camizestrant), FDA‑Approved for HR+, HER2- Advanced Breast Cancer with Emergent ESR1 Mutation, Available at Biologics by McKesson
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by AstraZeneca as a limited distribution specialty pharmacy provider for ETCAMAH® (camizestrant).
PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.